Literature DB >> 10452250

The marked anticancer effect of combined VCR, MTX, and indomethacin against drug-resistant recurrent small cell lung carcinoma after conventional chemotherapy: report of a case.

S Kobayashi1, S Okada, T Hasumi, N Sato, S Fujimura.   

Abstract

In a previous study, we discovered that indomethacin was an effective modulator of the sensitivity of pulmonary carcinoma cells to vincristine (VCR), methotrexate (MTX), adriamycin (ADR), and etoposide (VP-16). We describe herein the case of a 61-year-old-man with multiple brain, lung, liver, and bone metastases from small cell lung carcinoma (SCLC) that recurred after intensive chemotherapy, who showed no signs of remission following conventional chemotherapy. The general condition of the patient deteriorated until he required morphine sulfate to control his severe diffuse pain. In an attempt to improve this patient's quality of life (QOL), he was discharged from hospital and treated at the outpatient clinic with modulation therapy using indomethacin as an anodyne instead of morphine sulfate. Signs of almost complete remission to only one cycle of combination therapy with VCR, MTX, and indomethacin were observed without any obvious adverse effects. This case report serves to demonstrate that modulation therapy combined with VCR, MTX, and indomethacin may be useful in the treatment of patients with drug-resistant recurrent SCLC.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10452250     DOI: 10.1007/BF02482998

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  10 in total

1.  Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: a randomized study.

Authors:  Y Humblet; M Symann; A Bosly; L Delaunois; C Francis; J Machiels; M Beauduin; C Doyen; P Weynants; J Longueville
Journal:  J Clin Oncol       Date:  1987-12       Impact factor: 44.544

2.  Enhancement of etoposide and methotrexate sensitivity by indomethacin in vitro.

Authors:  R D Maca
Journal:  Anticancer Drug Des       Date:  1991-11

3.  Intensive chemotherapy with autologous bone marrow transplantation for small-cell lung cancer.

Authors:  R L Souhami; H T Hajichristou; D W Miles; H M Earl; P G Harper; C M Ash; A H Goldstone; S G Spiro; D M Geddes; J S Tobias
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

4.  Indomethacin enhances the cytotoxicity of VCR and ADR in human pulmonary adenocarcinoma cells.

Authors:  S Kobayashi; S Okada; H Yoshida; S Fujimura
Journal:  Tohoku J Exp Med       Date:  1997-03       Impact factor: 1.848

5.  Cyclic alternating combination chemotherapy for small cell bronchogenic carcinoma.

Authors:  M H Cohen; D C Ihde; P A Bunn; B E Fossieck; M J Matthews; S E Shackney; A Johnston-Early; R Makuch; J D Minna
Journal:  Cancer Treat Rep       Date:  1979-02

6.  Studies on the mechanism by which indomethacin increases the anticancer effect of methotrexate.

Authors:  A Bennett; J D Gaffen; P B Melhuish; I F Stamford
Journal:  Br J Pharmacol       Date:  1987-05       Impact factor: 8.739

7.  Immune modulatory effects of indomethacin in melanoma patients are not related to prostaglandin E2-mediated suppression.

Authors:  A B Tilden; C M Balch
Journal:  Surgery       Date:  1982-09       Impact factor: 3.982

8.  Growth inhibition of transplantable murine colon adenocarcinoma 38 by indomethacin.

Authors:  M Sato; T Narisawa; M Sano; T Takahashi; A Goto
Journal:  J Cancer Res Clin Oncol       Date:  1983       Impact factor: 4.553

9.  A clinical and pharmacokinetic study of indomethacin in standard and slow release formulations.

Authors:  K R Adams; L D Halliday; R G Sibeon; N Baber; T Littler; M L Orme
Journal:  Br J Clin Pharmacol       Date:  1982-08       Impact factor: 4.335

10.  Indomethacin therapy abrogates the prostaglandin-mediated suppression of natural killer activity in tumor-bearing mice and prevents tumor metastasis.

Authors:  P K Lala; R S Parhar; P Singh
Journal:  Cell Immunol       Date:  1986-04-15       Impact factor: 4.868

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.